Table 2. Direct healthcare-related economic burden in polycystic ovary syndrome (PCOS) as of 2021 in the United States.
|
Process/disorder |
Original year economic burden published (reference) | Economic burden year of publication (in billions)* | Economic burden in 2021 USD (in billions) | % of total economic burden |
|---|---|---|---|---|
| Initial evaluation | 2004 (2) | $0.093 | 0.166 | 1.09 |
| Menstrual dysfunction/AUB | 2004 (2) | $1.350 | 2.408 | 15.88 |
| Infertility care | 2004 (2) | $0.533 | 0.951 | 6.27 |
| Hirsutism | 2004 (2) | $0.622 | 1.109 | 7.31 |
| GDM† | 2020 (3) | $0.672† | 0.684 | 4.51 |
| gHTN† | 2021 (3) | $0.208† | 0.212 | 1.40 |
| Preeclampsia† | 2022 (3) | $0.137† | 1.400 | 9.23 |
| T2DM | 2023 (3) | $1.500 | 1.527 | 10.07 |
| Stroke | 2024 (3) | $2.400 | 2.445 | 16.12 |
| Anxiety | 2021 | Present study | 1.939 | 12.79 |
| Depression | 2021 | Present study | 1.678 | 11.07 |
| Eating disorders | 2021 | Present study | 0.644 | 4.25 |
| Total | 15.163 | 100.00 |
*
Updated for inflation using medical CPI (https://www.in2013dollars.com/Medical-care-services/price-inflation).
†
Estimates of economic burden in prior publication updated for inflation using medical CPI (https://www.in2013dollars.com/Medical-care-services/price-inflation).